Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib;Klinische erfahrungen in der anwendung von pegaptanib bei der behandlung der exsudativen altersabhängigen makuladegeneration (AMD)

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 6, 2008, Pages 582-587

  Maier, Mathias ^a   Feucht, N ^a   Huebner, M ^a   Lohmann, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Choroid; Retina; Vitreous

Indexed keywords

PEGAPTANIB; VASCULOTROPIN;

ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PRACTICE; EYE; EYE EXAMINATION; HISTORY; HUMAN; INJECTION; INTRAOCULAR PRESSURE; RETINA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; THICKNESS; THROMBOEMBOLISM; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 47649108265     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027474     Document Type: Article

References (26)

1. Adamis AP, Shima TS. The role of vascular endothelial growth factor in ocular disease. Retina 2005; 25: 111-118
2. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (3): 363-372
3. Bernatchez PN, Rollin S, Soker S et al. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem 2002; 85: 629-639
4. Bird AC. Age-related macular disease. Br J Ophthalmol 1996; 80: 1-2
5. Brown DM, Kaiser PK, Michels M et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; Oct 5; 355 (14): 1432-1444
6. Dafer RM, Schneck M, Friberg TR et al. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007; 22 (3): 201-204
7. D'Amico DJ. Results of the second year of Macugen for the treatment of neovascular AMD (V.I.S.I.O.N). Abstract presented at the American Society of Retinal Specialists Meeting. Montreal, 2005
8. D'Amico DJ, Masonson HN, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113 (6): 992-1001
9. Drolet DW, Nelson J, Tucker CE et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000; 17 (12): 1503-1510
10. Gragoudas ES, Adamis AP, Cunningham Jr ET et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816
11. Ishida S, Usui T, Yamashiro K et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198: 483-489
12. Matsuoka M, Ogata N, Otsuji T et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88: 809-815
13. Mennel S, Callizo J, Schmidt JC et al. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastintrade mark) injections. Acta Ophthalmol Scand 2007; 85 (6): 689-690 (Epub 2007)
14. Michels S, Rosenfeld PJ. Therapie der neovaskulären altersbedingten Makuladegeneration mit Ranibizumab/Lucentis. Klin Monatsbl Augenheilkd 2005; 222: 480-484
15. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006; 21 (4): 97
16. Schwesinger G, Yee C, Rohan RM et al. Intrachoroideal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001; 158: 1161-1172
17. Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; Oct 5; 355 (14): 1419-1431
18. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical results. Ophthalmol Clin North Am 2006; 19 (3): 361-372
19. Rosenfeld PJ, Fung AE, Lalwanil GA et al. Visual Outcomes Following a Variable-Dosing Regimen for Ranibizumab (LucentisTM) in Neovascular AMD: The PrONTO Study. Invest Ophthalmol Vis Sci 2006; 47: 2958; ARVO E-Abstract
20. Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26 (4): 383-390
21. Spilsbury K, Garrett KL, Shen WY et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157: 135-144
22. Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheikd 2006; 223: 271-278
23. Takeda A, Hata Y, Shiose S et al. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol 2003; 241: 765-772
24. Tilton RG, Chang KC, Lejeune WS et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999; 40: 689-696
25. Thakker GD, Hajjar DP, Muller WA et al. The role of phospatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999; 274: 10002-10007
26. Avastin prescribing information Genentech Incwww.gene.com2007